EHA 2025 | Promising agents in the treatment of CLL: BTK degraders and novel BCL2 inhibitors

Definitely the BTK degraders and I think that it will be, you know, like we are seeing that they have activity on patients that have relapse after the use of covalent BTK inhibitors and venetoclax or BCL2 inhibitor. That to me is very welcome because we need something to salvage our patients. And I did not see, like I saw the data with sonrotoclax, which is a new BCL2 inhibitor that is moving up in the clinical development. It’s not yet approved by the FDA for use, only accessible in clinical trials. It’s looking really good, but I don’t see a big impact in the sense that, oh, this is going to be like a game changer. I think it’s good to have different drugs available for patients because sometimes patients can develop a side effect or toxicity that may not allow them to continue with one particular drug. And if you have something else in the same family of medications that work similarly, you could potentially change, you know, for tolerability issues. So the development of new BCL2 inhibitors, the three highlights. And then the other one is, like I said, the BTK degraders that may be even interesting to see what would happen when you compare them with a drug such as pirtobrutinib that as of right now is the one commercially available drug that we have for patients that are double refractory. And I believe that there might be a Phase III trial in development. I’m not sure it’s still approved yet, but that’s one of the things that I am looking forward to just based on the preliminary data that looks so good. And it’s looking very safe. So I’m very excited, honestly because it’s a different way to target the same pathway.

This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.